INSM Insider: 56,520 Options Exercised; 76,520 Shares Sold Under 10b5-1
Rhea-AI Filing Summary
INSMED Inc (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer, completed multiple transactions on 09/12/2025 under a 10b5-1 plan. She exercised 56,520 stock options with a $23.75 exercise price, resulting in ownership of 56,520 shares from the exercise and a reported pre-sale beneficial ownership of 112,981 shares. On the same date she sold a total of 76,520 shares in four separate sell transactions at weighted average prices of $144.6, $145.67, $146.57, and $147.46, leaving her with 36,461 shares beneficially owned following the reported transactions. The sales were effected pursuant to a 10b5-1 trading plan adopted June 13, 2025, and the filing is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Option exercise at $23.75 yielded a substantial gain opportunity given subsequent sale prices above $144 per share.
- Transactions effected under a 10b5-1 trading plan, indicating pre-established, rule-compliant disposition of shares.
Negative
- Large net reduction in beneficial ownership: beneficial shares fell to 36,461 after selling 76,520 shares.
- Significant volume sold on single date (76,520 shares) could be perceived negatively by some investors monitoring insider holdings.
Insights
TL;DR: Officer exercised options at $23.75 then sold most shares under a 10b5-1 plan, reducing beneficial ownership materially.
The filing shows an in-the-money option exercise converting 56,520 options into shares at a low exercise price of $23.75, followed by contemporaneous market sales of 76,520 shares at weighted average prices between $144.06 and $148.00 per share under a 10b5-1 plan adopted June 13, 2025. The net effect is a reduction in reported beneficial ownership to 36,461 shares. These are routine, pre-planned transactions rather than ad hoc dispositions; materiality lies in the size of the sales relative to the reporting person's prior ownership.
TL;DR: Transactions appear compliant with Rule 10b5-1; documentation notes weighted-average pricing disclosures and attorney-in-fact signature.
The Form 4 discloses adoption of a 10b5-1 plan (June 13, 2025) and provides weighted-average sale price ranges with commitments to provide per-price breakdowns on request, which aligns with disclosure norms. The filing is executed by an attorney-in-fact, and option vesting details are provided. No indications of insider timing or amendments are present in the filing; the pattern is consistent with pre-arranged liquidity planning by an executive.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 56,520 | $0.00 | -- |
| Exercise | Common Stock | 56,520 | $23.75 | $1.34M |
| Sale | Common Stock | 32,091 | $144.60 | $4.64M |
| Sale | Common Stock | 30,967 | $145.67 | $4.51M |
| Sale | Common Stock | 7,304 | $146.57 | $1.07M |
| Sale | Common Stock | 6,158 | $147.46 | $908K |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 32,091 shares sold at prices ranging from $144.06 to $145.05 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 30,967 shares sold at prices ranging from $145.06 to $146.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 7,304 shares sold at prices ranging from $146.08 to $147.06 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 6,158 shares sold at prices ranging from $147.12 to $148.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
